• Aarti Drugs consolidated revenues for the quarter ended December (Q4FY22) were up 9% quarter-on-quarter (QoQ). On a year-on-year (YoY) basis, it witnessed a growth of 39%.
  • Its expenses for the quarter were up 11% QoQ and 43% YoY.
  • While the company reported 5% QoQ net profit decline, the same was up by 7% on a YoY basis.
  • The earnings per share (EPS) of Aarti Drugs stood at 6 during Q4FY22.

Aarti Drugs Financial Statements for Q4FY22:

(Rs, crores) Q4FY21 Q3FY22 Q4FY22 QoQ (%) YoY (%)
Total Income 503 641 697 9% 39%
Total Expenses 437 563 627 11% 43%
Profit before tax 65 79 71 -10% 8%
Tax 14 20 15 -26% 12%
Profit after tax 52 58 55 -5% 7%
Earnings per share 5.5 6.3 6.0    

Data Source: BSE, Company announcements

Want to keep a tab on Indian listed companies? Open an account and get daily stock research updates from Kotak Securities.

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

浩方电竞 pc蛋蛋28下载手机版 pc28加拿大开奖详情及时 英雄联盟竞猜现场投注网 09电竞下注抽注官网 英雄联盟平台赛程